Dr Jörg-Thomas Dierks has 30 years of healthcare experience, having held several senior executive positions in the pharmaceutical industry. Most recently, he has been the CEO of Meda, a Sweden-based specialty pharma company, a position he has held since 2013. Before becoming CEO, Jörg was the Chief Operating Officer (COO) for Meda from 2005 to 2013 and also assumed the role of Chief Scientific Officer (CSO) for a period of time. He was instrumental in growing the business over many years and leading its sale to Mylan in 2016 for $10bn. Prior to Meda, Jörg was the COO of Viatris, a Germany-based pharmaceutical company.
Born in Bad Kreuznach, Germany, Dr Dierks graduated from Johannes-Gutenberg-Universität zu Mainz. After one year in a hospital in Koblenz in 1986 he completed his studies with a degree in human medicine as medical doctor. One year later, Jörg was awarded the title of Doctor of Medicine. Dr Dierks also studied in Business Administration for Scientists at the Fernuniversität Gesamthochschule in Hagen.
Lluís Pérez has a professional background focused in the Corporate Finance Control and the Finance fields, having an extensive international experience in large multiple locations companies.
The professional career of Lluís has been developed for more than eight years as Group CFO in different Business Units of the second largest producer of steel in Europe, Celsa Group (in the UK, Scandinavia and Poland) and, being Group CFO of Goldcar (private equity owned) his last position.
He is an expert in the integration of subsidiaries, in coordinating multi-sites Finance departments, refinancings and in analyse feasibility of new investments and lead M&A processes.
Lluís holds a BS in Business Economics from the Universitat Autònoma de Barcelona and an E-MBA.
Dr Christoph Koch is Chief Business Development Officer at Neuraxpharm looking after the group’s product portfolio which includes both in- and out-licensing activities as well as growing Neuraxpharm’s footprint through M&A activities.
Christoph joined Neuraxpharm in August 2017, coming from DSM Sinochem Pharmaceuticals, where he has been building the B2B licensing of Drug Products.
Originally a scientist with a Ph.D. in Organic Chemistry from the University of Cologne, Christoph has more than 15 years’ industry experience having previously worked in leading BD roles for Heumann Pharma, the German subsidiary of Torrent Pharmaceuticals, and Helm in Hamburg.
Christoph has lived in Belgium, Germany and the Netherlands and is now based in Barcelona.
Burghard Burczyk has more than twenty years of leadership experience in international companies being an expert in successfully implementing strategic planning in purchasing, production, technology and supply chain.
He has a proven track record in product transfer and in procurement management within several pharmaceutical companies, including Haupt Pharma, Aristo and Ethypharm. At the same time, Burghard Burczyk has extensive experience as strategic consultant in supply chain and tender business.
Burghard holds a Degree in Mechanical Engineering from the University of Magdeburg, Germany.